SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Primary Eosinophilic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)

Status: Active

Description

This is a non-randomized open label multi-center study. Patients with high-risk myeloproliferative neoplasms (systemic mastocytosis [SM], advanced symptomatic primary eosinophilic disorder [PED], myelofibrosis [MF], and chronic myelomonocytic leukemia [CMML]) will be treated with SL-401, which will be administered as a brief intravenous infusion for 3 consecutive days initially every 21 days for 4 cycles; every 28 days for cycles 5-7; then every 42 days. Stage 1 will consist of a period in which several doses of SL-401 are evaluated. The Stage 2 portion will enroll up to 30 patients each with one of the two myeloproliferative malignancies: MF and CMML. In entirety, the Stage 2 portion will consist of up to 60 patients who will be treated at a maximum tolerated dose or maximum tested dose in which multiple dose-limiting toxicities are not observed (identified in Stage 1).

Eligibility Criteria

Inclusion Criteria

  • Inclusion Criteria: All Patients (Stages 1 and 2): 1. The patient is ≥18 years old. 2. The patient has an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2. 3. The patient has adequate baseline organ function, including cardiac, renal, and hepatic function: - Left ventricular ejection fraction (LVEF) ≥ institutional lower limit of normal as measured by multigated acquisition scan or 2-dimensional (2-D) echocardiogram within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead electrocardiogram (ECG) - Serum creatinine ≤1.5 mg/dL (or ≤114 µmol/L) - Serum albumin ≥3.2 g/dL (or ≥32 g/L) in the absence of receipt of (IV) albumin within the previous 72 hours - Bilirubin ≤1.5 mg/dL (or ≤26 µmol/L) - Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 times the upper limit of normal (ULN) - CPK ≤2.5 times the ULN 4. If a woman of child bearing potential, the patient has a negative serum or urine pregnancy test within 1 week prior to SL-401 treatment (intervals shorter than 1 week are acceptable, if required by institutional guidelines). 5. The patient has signed informed consent prior to initiation of any study-specific procedures or treatment. 6. The patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for response assessments. 7. The patient (either male or female) agrees to use acceptable contraceptive methods for the duration of time in the study, and to continue to use acceptable contraceptive methods for 2 months after the last SL-401 infusion. 8. Patient has an absolute neutrophil count (ANC) ≥0.5×10⁹/L. Additional Inclusion Criteria Specific to Patients with MF and CMML (Stages 1 and 2) Exclusion Criteria: All Patients (Stages 1 and 2): 1. Patient has persistent clinically significant toxicities Grade ≥2 from previous chemotherapy not readily controlled by supportive measures (excluding alopecia, nausea, and fatigue). 2. Patient has received treatment with chemotherapy, wide-field radiation, or biologic therapy within 14 days of study entry. 3. Patient has received treatment with another investigational agent within 14 days of study entry or concurrent treatment with another investigational agent. 4. Patient has previously received treatment with SL-401 or has a known hypersensitivity to any components of the drug product. 5. Patient has an active malignancy and/or cancer history (excluding myeloproliferative disorders and concomitant myeloid malignancies as specified in the inclusion criteria) that can confound the assessment of the study endpoints. Patients with a past cancer history (within 2 years of entry) and/or ongoing active malignancy or substantial potential for recurrence must be discussed with the Sponsor before study entry. Patients with the following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ (including superficial bladder cancer), cervical intraepithelial neoplasia, or organ-confined prostate cancer with no evidence of progressive disease. 6. Patient has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction or stroke within 6 months of study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication). 7. Patient has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that, in the Investigator's opinion, would put the patient at significant risk for pulmonary complications during the study. 8. Patient has known active or suspected disease involvement of the central nervous system (CNS). If suspected due to clinical findings, CNS disease should be ruled out with relevant imaging and/or examination of cerebrospinal fluid. 9. Patient is receiving immunosuppressive therapy, with the exception of corticosteroids as specified in the inclusion criteria and tacrolimus, for treatment or prophylaxis of graft-versus-host disease (GVHD). If the patient has been on immunosuppressive treatment or prophylaxis for GVHD, the treatment(s) must have been discontinued at least 14 days prior to study drug and there must be no evidence of Grade ≥2 GVHD. 10. Patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness that would limit compliance with study requirements. 11. Patient is pregnant or breast feeding. 12. Patient has known human immunodeficiency virus (HIV). 13. Patient has evidence of active or chronic Hepatitis B or Hepatitis C infection. 14. Patient is oxygen-dependent. 15. Patient has any medical condition that in the Investigator's opinion place the patient at an unacceptably high risk for toxicities. Additional Exclusion Criteria Specific to Patients with MF and CMML (Stages 1 and 2)

Locations & Contacts

California

Duarte
City of Hope Comprehensive Cancer Center
Status: Active
Contact: Haris Ali
Phone: 626-256-4673ext6268
Email: harisali@coh.org
Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Status: Active
Contact: Gary John Schiller
Phone: 310-825-5513
Email: gschiller@mednet.ucla.edu

Kansas

Fairway
University of Kansas Clinical Research Center
Status: Active
Name Not Available
Kansas City
University of Kansas Cancer Center
Status: Active
Name Not Available
Westwood
University of Kansas Hospital-Westwood Cancer Center
Status: Active
Name Not Available

Minnesota

Rochester
Mayo Clinic
Status: Active
Contact: Animesh Dev Pardanani
Phone: 855-776-0015
Email: pardanani.animesh@mayo.edu

New York

Buffalo
Roswell Park Cancer Institute
Status: Active
Name Not Available

Ohio

Cleveland
Case Comprehensive Cancer Center
Status: In review
Contact: Hetty Eileen Carraway
Phone: 410-955-8804
Email: jhcccro@jhmi.edu

Texas

Houston
M D Anderson Cancer Center
Status: Active
Contact: Naveen Pemmaraju
Phone: 713-792-4956
Email: npemmaraju@mdanderson.org

Trial Phase & Type

Trial Phase

Phase I/II

Trial Type

Treatment

Lead Organization

Lead Organization
Stemline Therapeutics, Inc.

Trial IDs

Primary ID STML-401-0314
Secondary IDs NCI-2015-00337
Clinicaltrials.gov ID NCT02268253